262 related articles for article (PubMed ID: 33272595)
1. Statins Inhibit Toll-Like Receptor 4-Mediated Growth of Human Esophageal Adenocarcinoma Cells.
Gergen AK; Kohtz PD; Halpern AL; White AM; Meng X; Fullerton DA; Weyant MJ
J Surg Res; 2021 Apr; 260():436-447. PubMed ID: 33272595
[TBL] [Abstract][Full Text] [Related]
2. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells.
Sadaria MR; Reppert AE; Yu JA; Meng X; Fullerton DA; Reece TB; Weyant MJ
J Thorac Cardiovasc Surg; 2011 Nov; 142(5):1152-60. PubMed ID: 22014341
[TBL] [Abstract][Full Text] [Related]
3. Toll-Like Receptor-4 Is a Mediator of Proliferation in Esophageal Adenocarcinoma.
Kohtz PD; Halpern AL; Eldeiry MA; Hazel K; Kalatardi S; Ao L; Meng X; Reece TB; Fullerton DA; Weyant MJ
Ann Thorac Surg; 2019 Jan; 107(1):233-241. PubMed ID: 30292843
[TBL] [Abstract][Full Text] [Related]
4. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells.
Ogunwobi OO; Beales IL
Am J Gastroenterol; 2008 Apr; 103(4):825-37. PubMed ID: 18371146
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice.
Santander S; Cebrián C; Esquivias P; Conde B; Esteva F; Jiménez P; Ortego J; Lanas A; Piazuelo E
Int J Oncol; 2012 Feb; 40(2):527-34. PubMed ID: 21971589
[TBL] [Abstract][Full Text] [Related]
6. Statin pretreatment inhibits the lipopolysaccharide-induced epithelial-mesenchymal transition via the downregulation of toll-like receptor 4 and nuclear factor-κB in human biliary epithelial cells.
Kim Y; Lee EJ; Jang HK; Kim CH; Kim DG; Han JH; Park SM
J Gastroenterol Hepatol; 2016 Jun; 31(6):1220-8. PubMed ID: 26574150
[TBL] [Abstract][Full Text] [Related]
7. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo.
Fujihara S; Morishita A; Ogawa K; Tadokoro T; Chiyo T; Kato K; Kobara H; Mori H; Iwama H; Masaki T
Oncotarget; 2017 Jan; 8(5):8536-8549. PubMed ID: 28052030
[TBL] [Abstract][Full Text] [Related]
8. Atorvastatin attenuates experimental contrast-induced acute kidney injury: a role for TLR4/MyD88 signaling pathway.
Yue R; Zuo C; Zeng J; Su B; Tao Y; Huang S; Zeng R
Ren Fail; 2017 Nov; 39(1):643-651. PubMed ID: 28805489
[TBL] [Abstract][Full Text] [Related]
9. Isoforms of RNF128 Regulate the Stability of Mutant P53 in Barrett's Esophageal Cells.
Ray D; Ray P; Ferrer-Torres D; Wang Z; Nancarrow D; Yoon HW; San Martinho M; Hinton T; Owens S; Thomas D; Jiang H; Lawrence TS; Lin J; Lagisetty K; Chang AC; Beer DG
Gastroenterology; 2020 Feb; 158(3):583-597.e1. PubMed ID: 31715145
[TBL] [Abstract][Full Text] [Related]
10. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes.
Methe H; Kim JO; Kofler S; Nabauer M; Weis M
Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1439-45. PubMed ID: 15860745
[TBL] [Abstract][Full Text] [Related]
11. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
[TBL] [Abstract][Full Text] [Related]
12. Involvement of the p38 pathway in the differential induction of heme oxygenase-1 by statins in Neuro-2A cells exposed to lipopolysaccharide.
Hsieh CH; Jeng JC; Hsieh MW; Chen YC; Lu TH; Rau CS; Jeng SF
Drug Chem Toxicol; 2011 Jan; 34(1):8-19. PubMed ID: 20954800
[TBL] [Abstract][Full Text] [Related]
13. Acetylsalicylic Acid Exhibits Antitumor Effects in Esophageal Adenocarcinoma Cells In Vitro and In Vivo.
Piazuelo E; Esquivias P; De Martino A; Cebrián C; Conde B; Santander S; Emperador S; García-González MA; Carrera-Lasfuentes P; Lanas A
Dig Dis Sci; 2016 Oct; 61(10):2896-2907. PubMed ID: 27343037
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin down-regulates osteogenic response in cultured human aortic valve interstitial cells.
Jarrett MJ; Yao Q; Venardos N; Weyant MJ; Reece TB; Meng X; Fullerton DA
J Thorac Cardiovasc Surg; 2021 Apr; 161(4):e261-e271. PubMed ID: 31924353
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin suppresses LPS-induced rapid upregulation of Toll-like receptor 4 and its signaling pathway in endothelial cells.
Wang Y; Zhang MX; Meng X; Liu FQ; Yu GS; Zhang C; Sun T; Wang XP; Li L; Wang YY; Ding SF; Yang JM; Zhang Y
Am J Physiol Heart Circ Physiol; 2011 May; 300(5):H1743-52. PubMed ID: 21317307
[TBL] [Abstract][Full Text] [Related]
16. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study.
Nguyen T; Duan Z; Naik AD; Kramer JR; El-Serag HB
Gastroenterology; 2015 Nov; 149(6):1392-8. PubMed ID: 26208896
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins.
Konturek PC; Burnat G; Hahn EG
J Physiol Pharmacol; 2007 Aug; 58 Suppl 3():141-8. PubMed ID: 17901590
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin decreases Toll-like receptor 4 expression and downstream signaling in human monocytic leukemia cells.
Yang SS; Li R; Qu X; Fang W; Quan Z
Cell Immunol; 2012 Sep; 279(1):96-102. PubMed ID: 23103560
[TBL] [Abstract][Full Text] [Related]
19. Secretory Phospholipase A2 IIa Mediates Expression of Growth Factor Receptors in Esophageal Adenocarcinoma.
Halpern AL; Kohtz PD; White AM; Houk AK; Rehring JF; Hanson L; McCarter MD; Joshi M; Meng X; Fullerton DA; Weyant MJ
Dig Dis Sci; 2021 Mar; 66(3):784-795. PubMed ID: 32277371
[TBL] [Abstract][Full Text] [Related]
20. Simvastatin Inhibits Histologic Changes Associated with Gastroduodenal Reflux in a Murine Model.
Gergen AK; Madsen HJ; Li A; Cheng L; Meng X; Fullerton DA; Pratap A; Weyant MJ
Dig Dis Sci; 2022 Oct; 67(10):4732-4741. PubMed ID: 35001242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
